AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop

Mar 09, 2021•over 4 years ago

Amount Raised

$36 Million

Round Type

series a

Seattle

Description

Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders

Company Information

Company

Presbyopia

Location

Seattle, Washington, United States

About

Presbyopia is the loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins when adults are in their 40s, and becomes almost universal by age 50.1 Presbyopia impacts billions of people globally with approximately 123 million adults affected in the U.S. alone.2 Reading glasses are the most common solution for near-vision correction. However, many people often find glasses inconvenient and/or prefer not to wear them for aesthetic reasons. Currently, there are no FDA-approved medications for presbyopia.

Company News

(2 articles)

Wed, 22 Mar 2023 07:00:00 GMT

Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL - Business Wire

Thu, 20 Apr 2023 07:00:00 GMT

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF - Business Wire

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech